José Mordoh - Fundación Instituto Leloir


Our main objective is to enhance immunostimulation and reduce immunosupression in cancer. In order to achieve it, we investigate on anti-tumor dendritic cells vaccines (DCs) in experimental and human systems. We also study immunosupression and its possible reversion. We do research on tumor stem cells (TSC) in order to identify new antigens, signaling pahtways, and development of new drugs. In addition, we perform clinical assays to validate the results obtained in experimental systems
  • Dendritic cells (DCs) vaccines in experimental systems. Previous data had demonstrated that immunization with DCs produce poor migration of DCs to lymph nodes. We have shown that in the vaccination site there is a formation of tertiary lymphoid structures.
  • Dendritic cells (DCs) vaccines in human systems. Vaccination with DCs loaded with irradiated allogeneic cells enhanced survival of melanoma patients. We are now analyzing how to augment the immunogenicity of those vaccines.
  • In 2009 the ANMAT approved a Phase II/III Clinical Study on 108 melanoma patients, using the vaccine CSF 470, randomized against interferon. This assay is being carried out at the Instituto Alexander Fleming, Buenos Aires, Argentina.
  • Research on tumor stem cells (TSC). We shall characterize the cells with clonogenic capacity from melanoma and colorectal tumors. We will also study new antigens by cDNA arrays. We will try to establish an antigenic profile typical of TSC, and will produce a phage library of llama antibodies against melanoma. Our research will also include the study of signaling pathways in order to design specific antagonists.
  • To develop those projects we are using RT-PCR, real-time PCR, genetic engineering, molecular biology, immunohistochemistry, confocal microscopy, flow cytometry, tissue culture, lipids analysis, ELISPOT, phage library construction, Laser Microdissection (LMD) and antibody arrays techniques.

Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. Mordoh J, Pampena MB, Aris M, Blanco PA, Lombardo M, von Euw EM, Mac Keon S, Yépez Crow M, Bravo AI, O'Connor JM, Orlando AG, Ramello F, Levy EM, Barrio MM. Front Immunol. 2017 May 31;8:625. doi: 10.3389/fimmu.2017.00625. eCollection 2017

In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells. Madorsky Rowdo FP, Barón A, von Euw EM, Mordoh J. Oncol Rep. 2017 Mar;37(3):1367-1378. doi: 10.3892/or.2017.5363

Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15. Rocca YS, Roberti MP, Juliá EP, Pampena MB, Bruno L, Rivero S, Huertas E, Sánchez Loria F, Pairola A, Caignard A, Mordoh J, Levy EM.  Front Immunol. 2016 Oct 10;7:413. eCollection 2016.

Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine.  Pizzurro GA, Tapia IJ, Sganga L, Podhajcer OL, Mordoh J, Barrio MM. Cancer Immunol Immunother. 2015 Nov;64(11):1393-406. doi: 10.1007/s00262-015-1743-z

Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report. Aris M, Bravo AI, Barrio MM, Mordoh J. Front Immunol. 2015 Mar 30;6:144. doi: 10.3389/fimmu.2015.00144. eCollection 2015.

Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. Madorsky Rowdo FP, Baron A, Urrutia M, Mordoh J. Front Immunol. 2015 Mar 26;6:127. doi: 10.3389/fimmu.2015.00127.

Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade. Roberti MP, Juliá EP, Rocca YS, Amat M, Bravo AI, Loza J, Coló F, Loza CM, Fabiano V, Maino M, Podhorzer A, Fainboim L, Barrio MM, Mordoh J, Levy EM. Eur J Immunol. 2015 May;45(5):1560-9. doi: 10.1002/eji.201445353.

Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy.  Arriaga JM, Greco A, Mordoh J, Bianchini M. Mol Cancer Ther. 2014 May;13(5):1369-81. doi: 10.1158/1535-7163. MCT-13-0944

José Mordoh
Head of Laboratory -

Rosa Wainstok
Independent researcher CONICET

Soledad Mac Keon
Postdoctoral fellow

Florencia Madorsky Rowdo
PhD student CONICET

Sofía Bentivegna
PhD student CONICET